Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

SPECT assay of radiolabeled monoclonal antibodies

Technical Report ·
OSTI ID:5870347
The accurate determination of the biodistribution of radiolabeled monoclonal antibodies (MoAbs) is important for calculation of dosimetry and evaluation of pharmacokinetic variables such as antibody dose and route of administration. A major long-term objective of this proposal is to determine the utility of single photon emission computed tomography (SPECT) for quantifying the biodistribution of monoclonal antibodies labeled with the clinically relevant radionuclide iodine-123 (I-123). The pharmacokinetics of I-123 labeled MoAbs will be determined by the SPECT in non-human primates. The errors associated with the SPECT measurements will be assessed with Monte Carlo simulations and by scanning phantoms containing I-123 activity in regions of uniform and nonuniform attenuation. The ability of SPECT to quantify I-123 distributions will be assessed, and new acquisition geometries and reconstruction algorithms for improved quantification will be evaluated. 33 refs.
Research Organization:
Duke Univ. Medical Center, Durham, NC (USA). Dept. of Radiology
Sponsoring Organization:
DOE; USDOE, Washington, DC (USA)
DOE Contract Number:
FG05-89ER60894
OSTI ID:
5870347
Report Number(s):
DOE/ER/60894-2; ON: DE91012158
Country of Publication:
United States
Language:
English

Similar Records

SPECT (single photon emission computed tomography) assay of radiolabeled monoclonal antibodies
Technical Report · Sat Mar 31 23:00:00 EST 1990 · OSTI ID:7100325

SPECT assay of radiolabeled monoclonal antibodies
Technical Report · Fri Jan 31 23:00:00 EST 1992 · OSTI ID:7288347

SPECT assay of radiolabeled monoclonal antibodies. Third yearly progress report, September 1991--February 1992
Technical Report · Fri Jan 31 23:00:00 EST 1992 · OSTI ID:10170842